Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quizartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.99 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.99 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.99 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.99 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.99 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.99 |
| ▸ | MUSK | O15146 | 1/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.99 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.99 |
| ▸ | PAK3 | O75914 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.99 |
| ▸ | ABL1 | P00519 | 1/20 | 0.99 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.99 |
| ▸ | LCK | P06239 | 1/20 | 0.99 |
| ▸ | YES1 | P07947 | 1/20 | 0.99 |
| ▸ | LYN | P07948 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quizartinib SCHEMBL74121 | 1.00 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL742377 | 1.00 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL72923 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29349937 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL3453696 | 0.97 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL73633 | 0.96 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL742748 | 0.95 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL74122 | 0.95 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL72924 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL74399 | 0.94 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| CN-107427501-B | Methods of treating cancer by combination use | 第一三共株式会社 | 2023-12-01 | — | — | CN | claimed |
| CN-122094980-A | Bispecific antibody fusion molecules targeting CD180 and CD3 and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | disclosed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | CHINA MEDICAL UNIVERSITY (TW) | 2026-01-29 | — | — | US | disclosed |
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | disclosed |
| WO-2025245286-A2 | METHOD FOR DETECTING MYELOID-LINEAGE MALIGNANCIES/MYELOID MALIGNANCIES | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2023287128-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-01-19 | — | — | WO | disclosed |
| US-20220387435-A1 | USE OF MULTI-TARGET PROTEIN KINASE INHIBITOR | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-4056184-A1 | USE OF MULTI-TARGET PROTEIN KINASE INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022132936-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-23 | — | — | WO | disclosed |
| CN-114650826-A | Application of multi-target protein kinase inhibitor | 石药集团中奇制药技术（石家庄）有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220090175-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387435-A1 | USE OF MULTI-TARGET PROTEIN KINASE INHIBITOR | FLT3, TTK, DCK | FLT3 1/4885CSF1R 236/4885RET 92/4885 |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | CD4, TPMT, SLC11A2 | FLT3 784/4885CSF1R 2502/4885RET 418/4885 |
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | LDLR, NPC1L1, LPXN | FLT3 558/4885CSF1R 300/4885RET 460/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | FLT3 20/4885CSF1R 771/4885RET 11/4885 |
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | FLT3 1/4885CSF1R 63/4885RET 204/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | FLT3 1329/4885CSF1R 1666/4885RET 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.